Trexquant Investment LP Increases Stock Position in Inspire Medical Systems, Inc. $INSP

Key Points

• Trexquant Investment LP increased its stake in Inspire Medical Systems by 22.7% in the first quarter, owning approximately 0.14% of the company valued at $6,622,000.
• The company's stock received mixed ratings from analysts with a price target set as high as $230.00 by UBS Group, while JPMorgan Chase lowered its price target to $110.00.
• Inspire Medical Systems reported an earnings per share (EPS) of $0.45 for the last quarter, exceeding analyst estimates and showing a 10.8% year-over-year revenue increase.

Trexquant Investment LP grew its holdings in Inspire Medical Systems, Inc. (NYSE:INSP - Free Report) by 22.7% in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 41,576 shares of the company's stock after purchasing an additional 7,705 shares during the quarter. Trexquant Investment LP owned approximately 0.14% of Inspire Medical Systems worth $6,622,000 at the end of the most recent reporting period.

Several other large investors have also modified their holdings of the business. Landscape Capital Management L.L.C. purchased a new position in shares of Inspire Medical Systems in the 1st quarter worth approximately $1,220,000. Oak Associates Ltd. OH purchased a new position in shares of Inspire Medical Systems in the 1st quarter worth approximately $1,081,000. Beck Bode LLC grew its position in shares of Inspire Medical Systems by 5.2% in the 1st quarter. Beck Bode LLC now owns 36,520 shares of the company's stock worth $5,817,000 after buying an additional 1,809 shares during the last quarter. B. Metzler seel. Sohn & Co. AG grew its position in shares of Inspire Medical Systems by 39.2% in the 1st quarter. B. Metzler seel. Sohn & Co. AG now owns 18,687 shares of the company's stock worth $2,976,000 after buying an additional 5,262 shares during the last quarter. Finally, Caisse DE Depot ET Placement DU Quebec grew its position in shares of Inspire Medical Systems by 2,038.3% in the 1st quarter. Caisse DE Depot ET Placement DU Quebec now owns 85,167 shares of the company's stock worth $13,565,000 after buying an additional 81,184 shares during the last quarter. Institutional investors own 94.91% of the company's stock.

Inspire Medical Systems Trading Up 0.9%

NYSE INSP traded up $0.83 on Tuesday, hitting $94.52. 824,467 shares of the company's stock traded hands, compared to its average volume of 1,646,523. Inspire Medical Systems, Inc. has a 1-year low of $73.92 and a 1-year high of $225.00. The firm's 50-day moving average price is $112.38 and its two-hundred day moving average price is $140.06. The firm has a market capitalization of $2.79 billion, a PE ratio of 54.64, a P/E/G ratio of 2.92 and a beta of 1.15.

Inspire Medical Systems (NYSE:INSP - Get Free Report) last posted its earnings results on Monday, August 4th. The company reported $0.45 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.22 by $0.23. Inspire Medical Systems had a net margin of 6.17% and a return on equity of 10.38%. The firm had revenue of $217.09 million during the quarter, compared to analysts' expectations of $214.50 million. During the same period in the previous year, the business posted $0.32 EPS. The business's revenue was up 10.8% compared to the same quarter last year. Inspire Medical Systems has set its FY 2025 guidance at 0.400-0.500 EPS. On average, research analysts anticipate that Inspire Medical Systems, Inc. will post 2.16 earnings per share for the current fiscal year.

Inspire Medical Systems announced that its Board of Directors has initiated a share buyback plan on Monday, August 11th that permits the company to repurchase $200.00 million in shares. This repurchase authorization permits the company to buy up to 8.6% of its shares through open market purchases. Shares repurchase plans are usually a sign that the company's management believes its stock is undervalued.

Insiders Place Their Bets

In other Inspire Medical Systems news, CFO Richard Buchholz sold 11,000 shares of the company's stock in a transaction on Friday, August 29th. The shares were sold at an average price of $93.39, for a total transaction of $1,027,290.00. Following the completion of the transaction, the chief financial officer directly owned 44,867 shares in the company, valued at approximately $4,190,129.13. This represents a 19.69% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Corporate insiders own 2.30% of the company's stock.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on INSP. KeyCorp downgraded shares of Inspire Medical Systems from an "overweight" rating to a "sector weight" rating in a research report on Tuesday, August 5th. UBS Group set a $230.00 target price on shares of Inspire Medical Systems and gave the stock a "buy" rating in a research report on Tuesday, August 5th. Leerink Partners dropped their target price on shares of Inspire Medical Systems from $116.00 to $97.00 and set a "market perform" rating on the stock in a research report on Friday, August 15th. Robert W. Baird boosted their target price on shares of Inspire Medical Systems from $230.00 to $236.00 and gave the stock an "outperform" rating in a research report on Tuesday, May 6th. Finally, Morgan Stanley dropped their target price on shares of Inspire Medical Systems from $200.00 to $182.00 and set an "overweight" rating on the stock in a research report on Tuesday, July 15th. Eight research analysts have rated the stock with a Buy rating and six have given a Hold rating to the company. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus target price of $164.50.

Inspire Medical Systems Profile

Inspire Medical Systems, Inc, a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA) in the United States and internationally. The company offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe OSA.